secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2025-12-16T23:59:59+00:00
Accession:  0001193125-25-320901
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV Technologies reports positive Phase 3 VITESSE results; BLA submission on track for H1 2026
--------------------------------------------------------------------------------

- VITESSE met primary endpoint: response rate 46.6% vs 14.8% placebo (p<0.001); lower bound CI 24.5% >15% threshold.
- Safety consistent with prior studies: low discontinuations (3.2% active vs 0.5% placebo), no treatment-related SAEs.
- BLA submission for 4-7 year olds planned for first half 2026; prior FDA Breakthrough Therapy Designation.
- Positive results trigger acceleration of ABSA and BS warrants exercise period through Jan 15, 2026.
- 654 children enrolled, largest food allergy immunotherapy trial; compliance 96.2%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312525320901/0001193125-25-320901-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312525320901/d28682d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-320901

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer